Improving breast cancer outcome predictions for high-risk populations
Leveraging high-risk populations for precision prevention: A novel approach for improving risk prediction for outcomes after a breast cancer diagnosis
This study is looking at how we can better predict breast cancer outcomes by including genetic information, especially for high-risk groups like Black women, to help doctors give more personalized treatment recommendations and improve survival rates.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10895315 on NIH RePORTER |
What this research studies
This research investigates how to enhance predictions of breast cancer outcomes by incorporating genetic factors, particularly focusing on high-risk groups such as Black women who face higher mortality rates. The study aims to develop a polygenic risk score that can be used alongside existing clinical markers to provide more accurate prognoses for breast cancer survivors. By analyzing data from the Breast Cancer Family Registry, the research seeks to identify additional factors that influence survival rates after a breast cancer diagnosis. This approach aims to address health disparities and improve personalized treatment recommendations for those at greatest risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include Black women diagnosed with breast cancer, particularly those with a family history of the disease or other risk factors.
Not a fit: Patients who do not have breast cancer or those who are not part of high-risk populations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of breast cancer outcomes, allowing for tailored treatment plans that improve survival rates.
How similar studies have performed: Previous research has shown promise in using genetic factors to improve cancer prognosis, indicating that this approach could yield significant advancements.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Zeinomar, Nur — Rutgers Biomedical and Health Sciences
- Study coordinator: Zeinomar, Nur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.